[Cisplatin schedule in combination with gemcitabine in unresectable non-small cell lung cancer].
Gemcitabine (on days 1, 8, and 15)-cisplatin (on day 15) combinations were used to treat 9 patients with unresectable non-small cell lung cancer to study efficacy and safety. Gemcitabine 1,000 mg/m2 was administered on days 1, 8, and 15 of a 28-day cycle. Cisplatin 60-65 mg/m2 was administered on day 15 of a 28-day cycle. Three cycles were planned per patient. The nine patients received 25 cycles of chemotherapy. Objective response rates was 55% (complete response 11% and partial response 44%). Stable disease was 33%, and progressive disease was 11%. Seven of 9 patients received the planned 3 cycles of therapy. Two patients received only 2 cycles, due to progressive disease (1 patient), and ulcerative colitis (1 patient). Grade 3 leukopenia was 22%, and grade 3 neutropenia was 11%. No grade 4 hematological toxicities were observed. Grade 3 anorexia was 11%, and grade 3 skin rash which occurred in the first cycle 22%. Our data show less toxicity and no significant difference in response rates, so the administration of cisplatin on day 15 seemed to be a useful and safe regimen.
Ohara
Tadashi
T
Dept. of Respiratory Medicine, Shiga Medical Center for Adults.
Nishimoto
Hiroshi
H
Shimada
Kazue
K
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine